Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of GenSci004 vs Genotropin in Pediatric GHD (ELEVATE)
NCT06007417Phase 3Not yet recruiting
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Dec 2023
- Primary completion
- May 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of peg-somatropin in growth hormone deficiency (GHD), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
peg-somatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT06007417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06007417.